{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:31Z","timestamp":1761870631612,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.clml.2014.06.001","type":"journal-article","created":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T14:43:46Z","timestamp":1402497826000},"page":"e183-e185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Amitriptyline-Induced Agranulocytosis With Bone\u00a0Marrow Confirmation"],"prefix":"10.1016","volume":"14","author":[{"given":"Natalya","family":"Azadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Kelemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.06.001_bib1","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.06.001_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0140-6736(63)92569-8","article-title":"Agranulocytosis due to amitriptyline","volume":"282","author":"Gault","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2014.06.001_bib3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archinte.159.4.369","article-title":"A\u00a0population-based case-cohort study of drug-associated agranulocytosis","volume":"159","author":"van der Klauw","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2014.06.001_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","article-title":"Idiosyncratic drug-induced agranulocytosis or acute neutropenia","volume":"15","author":"Andres","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2014.06.001_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ejim.2006.07.012","article-title":"Idiosyncratic drug-induced agranulocytosis: update of an old disorder","volume":"17","author":"Andr\u00e8s","year":"2006","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clml.2014.06.001_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00063030-199911030-00005","article-title":"Treatment of drug-induced agranulocytosis with haematopoietic growth factors: a review of the clinical experience","volume":"11","author":"Vial","year":"1999","journal-title":"BioDrugs"},{"key":"10.1016\/j.clml.2014.06.001_bib7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ajh.21433","article-title":"Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management","volume":"84","author":"Tesfa","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.06.001_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1179\/102453311X12902908411715","article-title":"Incidence, etiology and bone marrow characteristics of non-chemotherapy-induced agranulocytosis","volume":"16","author":"Apinantriyo","year":"2011","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2014.06.001_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1507\/endocrj.EJ12-0332","article-title":"The relationship between bone marrow characteristics and the clinical prognosis of antithyroid drug-induced agranulocytosis","volume":"60","author":"Yang","year":"2013","journal-title":"Endocr J"},{"key":"10.1016\/j.clml.2014.06.001_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","article-title":"How to manage neutropenia in multiple myeloma","volume":"12","author":"Palumbo","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2014.06.001_bib11","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.06.001_bib12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2011.08949.x","article-title":"A\u00a0comparison of lenalidomide\/dexamethasone versus cyclophosphamide\/lenalidomide\/dexamethasone versus cyclophosphamide\/bortezomib\/dexamethasone in newly diagnosed multiple myeloma","volume":"156","author":"Khan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.06.001_bib13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann Intern Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:42Z","timestamp":1761870342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014001347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S2152265014001347"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.06.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amitriptyline-Induced Agranulocytosis With Bone\u00a0Marrow Confirmation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}